Roche releases more Evrysdi data leading up to FDA decision for very young infants with SMA
One month away from an FDA decision on Evrysdi for infants under two months old, Roche’s Genentech has released new long-term data on its oral drug for spinal muscular atrophy (SMA).
The data show that, after three years of treatment, 91% of children who began taking the drug at ages 1-7 months were alive (n=58). In addition, of 48 children evaluated, 32 maintained and four gained the ability to sit without support.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.